Several research reports have shown increased HK-II expression in many malignant tumors, including nasopharyngeal cancer, ovarian cancer, renal cell carcinoma, hepatocellular carcinoma, colon cancer, and glioma [98–100]. This evidence concerns the gene HK2 and hepatocellular carcinoma.